EUVIMEDEUVIMED entdecken
Crossref

Antimicrobial activity of aztreonam–avibactam against KPC variant-producing Klebsiella pneumoniae with ceftazidime–avibactam resistance

Jingchun Kong, Zhuocheng Yao, Yanlei Zheng, Jia Zhang, Xiaotuan Zhang iD, Endian Sun, Changrui Qian, Yao Sun, Tieli Zhou iD

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Jingchun Kong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affilia…. Hauptthemen laut MEDLINE: Azabicyclo Compounds, Klebsiella pneumoniae, Aztreonam, beta-Lactamases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Planned Science and Technology Project of Wenzhou, Consortium for Infection and Innovation (CII), The First Affiliated Hospital of Wenzhou Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Klebsiella pneumoniae carbapenemase (KPC) mutations are a major mechanism of ceftazidime–avibactam resistance. We aimed to investigate the antimicrobial activity of aztreonam–avibactam against KPC variant-producing K. pneumoniae.

Methods

Antimicrobial susceptibility of 36 KPC variant-producing K. pneumoniae strains was determined by broth microdilution method. The bactericidal kinetic characteristics were analysed by time-kill assays. The interaction between aztreonam and avibactam was analysed by the checkerboard assay and inhibitory Emax model with a baseline effect parameter. blaKPC cloning, molecular docking and enzymatic kinetic analysis was performed to analyse the interactions between KPC variants and substrates. In vivo antibacterial activity was investigated using the Galleria mellonella infection model and the neutropenic mouse intraperitoneal infection model.

Results

Aztreonam–avibactam exhibited an MIC50 of 1 mg/L and an MIC90 of 2 mg/L against KPC variant-producing strains, with a rapid bactericidal effect; however, one KPC-14-producing strain showed resistance (8 mg/L). The inhibitory Emax model effectively fitted the observed values from checkerboard assay: aztreonam MICs decreased rapidly as avibactam concentration increased, and gradually reached a plateau. Despite a reduced susceptibility to avibactam inhibition, these KPC variants exhibit impaired aztreonam hydrolysis, with aztreonam MICs decreasing by 2- to 1024-fold relative to KPC-2. In vivo, aztreonam–avibactam significantly increased the survival rate of G. mellonella and reduced the bacterial load in the organs of mice infected with KPC variant-producing K. pneumoniae strain.

Conclusions

Aztreonam–avibactam represents an effective therapeutic option for KPC variant-producing K. pneumoniae.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Azabicyclo CompoundsKlebsiella pneumoniaeAztreonambeta-LactamasesAnti-Bacterial AgentsCeftazidimeBacterial ProteinsAnimalsMicrobial Sensitivity TestsKlebsiella InfectionsMiceDrug CombinationsDisease Models, AnimalLepidopteraMolecular Docking SimulationMothsFemale

Substanzen

Azabicyclo CompoundsAztreonamavibactam, ceftazidime drug combinationbeta-LactamasesAnti-Bacterial AgentsCeftazidimeBacterial ProteinsDrug Combinationscarbapenemaseavibactam

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province…
  • Department of Medical Inspection, Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People's Hospital, Wenzhou, Zhejiang, China.
  • Department of Clinical Laboratory, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan Province, China.

ORCID-Profile: Xiaotuan Zhang, Tieli Zhou

Förderung

  • Planned Science and Technology Project of Wenzhou
  • Consortium for Infection and Innovation (CII), The First Affiliated Hospital of Wenzhou Medical University

Zitieren

APA

Kong, J., Yao, Z., Zheng, Y., Zhang, J., Zhang, X., Sun, E., Qian, C., Sun, Y., & Zhou, T. (2026). Antimicrobial activity of aztreonam–avibactam against KPC variant-producing Klebsiella pneumoniae with ceftazidime–avibactam resistance. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag152

Vancouver

Kong J, Yao Z, Zheng Y, Zhang J, Zhang X, Sun E, et al. Antimicrobial activity of aztreonam–avibactam against KPC variant-producing Klebsiella pneumoniae with ceftazidime–avibactam resistance. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag152

BibTeX
@article{Kong2026,
  author = {Kong, Jingchun and Yao, Zhuocheng and Zheng, Yanlei and Zhang, Jia and Zhang, Xiaotuan and Sun, Endian and Qian, Changrui and Sun, Yao and Zhou, Tieli},
  title = {Antimicrobial activity of aztreonam–avibactam against KPC variant-producing Klebsiella pneumoniae with ceftazidime–avibactam resistance},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag152}
}
Kostenlos starten →